Table 4.
Impact of current VOCs on the neutralizing efficacy of vaccines.
|
B.1.1.7 (Alpha) | B.1.351 (Beta) | P.1 (Gamma) | B.1.617.2 (Delta) | B.1.1.529 (Omicron) | References | |
|---|---|---|---|---|---|---|---|
| RNA based platform | Pfizer-BioNTech Vaccine | ✓ | Neutralization efficacy slightly reduced | ✓ | Neutralization efficacy slightly reduced | Poor neutralizing efficacy | (61, 86, 87) |
| Moderna vaccine | ✓ | Neutralization efficacy slightly reduced | Neutralization efficacy slightly reduced | Neutralization efficacy slightly reduced | Poor neutralizing efficacy | (61, 87) | |
| Adenoviral Vector | Astra-Zeneca/Oxford vaccine (Covishield or Vaxzevria) | ✓ | Neutralization efficacy slightly reduced | ✓ | ✓ | Poor neutralizing efficacy | (86–90) |
| Gamelaya institute—Sputnik V | ✓ | Neutralization efficacy slightly reduced | ✓ | ✓ | Unclear | (91, 92)] | |
| Janssen vaccine | ✓ | ✓ | ✓ | ✓ | Poor neutralizing efficacy | (87, 93) | |
| Inactivated virus | Sinovac—CoronaVac | ✓ | Unclear | ✓ | Unclear | Unclear | WHO |
| Sinopharm BIBP vaccine | ✓ | ✓ | ✓ | ✓ | Unclear | WHO | |
| Bharat Biotech—Covaxin | ✓ | ✓ | ✓ | ✓ | Unclear | (94, 95) (bharatbiotech.com) | |
| Protein-Based | Novavax/Covovax (NVX-CoV2373) | ✓ | Neutralization efficacy slightly reduced | ✓ | ✓ | Unclear | (96) |